+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment



Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment



Przeglad Lekarski 65(12): 834-837



Despite major advances in cardiology dyslipidemia continues to be underdiagnosed and undertreated. The study aimed to evaluate current prevalence of dyslipidemia and treatment efficacy in both coronary and non-coronary subjects. 17,065 subjects aged 30-95 years (20.51%--coronary heart disease (CHD) patients), seeking medical help for disparate reasons from 675 family physicians, were randomly enrolled. Family physicians completed pertinent questionnaires against available medical records and measured patients' lipid levels during a single appointment. Dyslipidemia was detected in 73% of the CHD subjects vs. 46% of the non-CHD ones (p = 0.00001); its severity differing regionally. Hypolipemic treatment was administered to 82% of the CHD subjects vs. 12% of the non-CHD ones (p = 0.00001). Mean concentrations of LDL-cholesterol were higher in the treated subjects (p = 0.00002). Only 10% of the CHD subjects and 20% of the non-CHD ones were treated effectively for dyslipidemiae. Dyslipidemia was found widely prevalent nationwide, as well as poorly pharmacologically controlled in both primary and secondary prevention. Diversity of economic factors notwithstanding, this was mainly attributable to ineffective patient educational policies, meriting therefore immediate expansion and enhancement of existing disease management system in terms of adequate monitoring and effective treatment of key coronary risk factors.

(PDF emailed within 1 workday: $29.90)

Accession: 055157400

Download citation: RISBibTeXText

PMID: 19441674


Related references

Lipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004-2010). Atherosclerosis 263: E187-E187, 2018

Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?. Global Cardiology Science and Practice 2015(2): 19, 2015

Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. European Journal of Cardiovascular Prevention and Rehabilitation 18(2): 287-296, 2011

Analysis of reasons for discontinuation of treatment for dyslipidemia in secondary prevention of coronary heart disease. Przeglad Lekarski 56(11): 709-715, 2000

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317(20): 1237-1245, 1987

Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Wiener Klinische Wochenschrift 123(19-20): 611-617, 2012

Treatment of dyslipidemia in the secondary prevention of coronary artery disease. Duodecim; Laaketieteellinen Aikakauskirja 114(15): 1503-1508, 2001

Prevalence of dyslipidemia and borderline dyslipidemia and other risk factors of coronary heart disease in residents from Beijing communities. Zhonghua Xin Xue Guan Bing Za Zhi 38(2): 175-180, 2011

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. Bmc Cardiovascular Disorders 17(1): 160, 2018

The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. American Heart Journal 157(4): 709-15.E1, 2009

Time for implementation of hypolipemiant treatment in patient with dyslipidemia in general medicine: results of the Prysme study. Annales de Cardiologie et d'Angeiologie 61(1): 8-14, 2012

Management of dyslipidemia in the primary prevention of coronary heart disease. Current Opinion in Cardiology 17(5): 503-511, 2002

Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study. Preventive Cardiology 12(2): 65-71, 2009

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology 26(9): E330-E335, 2011

Dyslipidemia and coronary artery disease. Prevalence and treatment in patients referred for coronary arteriography. Cardiology 87(6): 497-501, 1996